DOI: 10.1128/AAC.01162-18
Article Information
PubMed
Published By
History
- Received June 1, 2018
- Returned for modification July 13, 2018
- Accepted August 11, 2018
- Published online October 24, 2018.
Copyright & Usage
Copyright © 2018 Banda et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
Article Versions
- Accepted Manuscript version (August 27, 2018).
- You are viewing the most recent version of this article.
Author Information
- Clifford G. Bandaa,b,
- Fraction Dzinjalamalaa,b,
- Mavuto Mukakaa,c,f,
- Jane Mallewaa,b,
- Victor Maidenb,
- Dianne J. Terlouwb,d,
- David G. Lallood,
- Saye H. Khooe and
- Victor Mwapasaa,b
- aUniversity of Malawi, College of Medicine, Blantyre, Malawi
- bMalawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi
- cOxford Centre for Tropical Medicine and Global Health, Oxford, United Kingdom
- dLiverpool School of Tropical Medicine, Liverpool, United Kingdom
- eUniversity of Liverpool, Liverpool, United Kingdom
- fMahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand
- Address correspondence to Clifford G. Banda, cgbanda{at}mlw.mw, or Victor Mwapasa, vmwapasa{at}medcol.mw.
Citation Banda CG, Dzinjalamala F, Mukaka M, Mallewa J, Maiden V, Terlouw DJ, Lalloo DG, Khoo SH, Mwapasa V. 2018. Impact of efavirenz-, ritonavir-boosted lopinavir-, and nevirapine-based antiretroviral regimens on the pharmacokinetics of lumefantrine and safety of artemether-lumefantrine in Plasmodium falciparum-negative HIV-infected Malawian adults stabilized on antiretroviral therapy. Antimicrob Agents Chemother 62:e01162-18. https://doi.org/10.1128/AAC.01162-18.
